Last reviewed · How we verify
NCT04382157
Magnesium Replacement and Hyperglycemia After Kidney Transplantation
Phase 1, PHASE2 trial testing Mablet 360 mg in Hypomagnesemia in 40 participants. Status unknown.
31 August 2022
Quick facts
| Lead sponsor | Oslo University Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 25 February 2020 |
| Primary completion | 31 August 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Mablet 360 mg — full drug profile →
- Placebo
Conditions studied
- Hypomagnesemia — all drugs for Hypomagnesemia →
- Kidney Transplantation — all drugs for Kidney Transplantation →
Sponsor
Oslo University Hospital
Who can join
18 and older, any sex, with Hypomagnesemia or Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The insulin receptor is dependent on magnesium and hypomagnesemia is associated with increased insulin resistance and decreased insulin secretion and action. Recent data suggest that hypomagnesemia may play a role in development of type 2 diabetes. Kidney transplantation patients have low plasma magnesium levels, partly due to treatment with calcineurin inhibitors. However, the role of magnesium in the development of post-transplant diabetes mellitus (PTDM) is unclear. The present study addresses, whether hypomagnesemia is feasible to reverse by oral administration of magnesium. The investigators wish to investigate whether oral magnesium supplementation is sufficient to increase magnesium levels in kidney transplant recipients, and if supplementation improves glycemic parameters as measured by an oral glucose tolerance test (OGTT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04382157
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypomagnesemia
Currently open trials in the same condition.
- NCT05998863 — EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy · Phase 3 · recruiting
Other Oslo University Hospital trials
Trials by the same sponsor.
- NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
- NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
- NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
- NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
- NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04382157 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
- Last refreshed: 28 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04382157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing